Medicine has long drawn a single line through the KRAS gene, treating all mutations as one verdict: resistant. A study published in Nature now asks whether that line was drawn too broadly, finding that colorectal cancers carrying the G13 variant of KRAS respond to anti-EGFR antibody therapy much as unmutated tumors do — while G12-mutant tumors remain resistant. In the slow work of precision oncology, this distinction is not merely academic; it is the kind of refinement that determines which patients are offered a chance at treatment and which are quietly turned away.
Nature
· Aug 18, 2026
· health
· 1 min de leitura
High
Apuração: Verificado
KRAS G13 mutations retain anti-EGFR sensitivity in colorectal cancer, unlike G12 variants
◉
Health & Medicine
7994 artigos relacionados
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% correspondência
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% correspondência
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Viés e Enquadramento
⚖
Nature research article presents scientific findings on KRAS mutations and anti-EGFR sensitivity with neutral, evidence-based framing typical of peer-reviewed scientific publishing.
Bias Direction
center
Confidence
HIGH
Objective scientific reporting using empirical findings from patient-derived organoid studies. The framing presents results as factual discoveries that challenge existing assumptions, using measured language appropriate to scientific discourse.
Clinical implementation challenges or barriers to adopting new biomarker classifications
Perspectives from pharmaceutical companies developing anti-EGFR therapies
Patient advocacy group viewpoints on treatment implications
Economic/healthcare system impact of revised treatment protocols
Impacto Geopolítico
🌎
This is a biomedical research article about cancer treatment, not a geopolitical matter requiring international relations analysis.
Escalation Risk
N/A
Confidence
HIGH
Lente Econômica
📈
KRAS G13 mutations show anti-EGFR drug sensitivity unlike G12 variants, potentially expanding treatment eligibility and market for existing therapies in colorectal cancer.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Oncology
Biotechnology
Healthcare/Medical Devices
Diagnostic Testing
Colorectal cancer patients with KRAS G13 mutations may gain access to effective anti-EGFR treatments previously thought ineffective, improving treatment options and potentially reducing out-of-pocket costs by expanding existing drug utility rather than requiring new therapies.
FDA and regulatory bodies may need to revise companion diagnostic requirements and treatment guidelines to differentiate KRAS G13 from G12 mutations. This could accelerate approval of refined biomarker tests and prompt label expansions for existing anti-EGFR monoclonal antibodies (cetuximab, panitumumab), affecting reimbursement policies.